Searchable abstracts of presentations at key conferences on calcified tissues

ba0002lb2 | (1) | ICCBH2013

WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta identify a key WNT ligand regulating bone mass

Laine Christine , Joeng Kyu Sang , Campeau Philippe , Kiviranta Riku , Tarkkonen Kati , Grover Monica , Lu James , Pekkinen Minna , Wessman Maija , Heino Terhi , Nieminen-Pihala Vappu , Laine Tero , Kroger Heikki , Cole William , Lehesjoki Anna-Elina , Krakow Deborah , Curry Cynthia , Cohn Daniel , Gibbs Richard , Lee Brendan , Makitie Outi

The role of the WNT pathway in skeletal maintenance has been extensively studied since the identification of mutations in key signaling WNT mediators (LRP5 and sclerostin) in high and low bone mass phenotypes. However, the identity of the key WNT ligand that signals via LRP5/6 has remained unknown. We aimed to identify genes with a major effect on the skeleton by studying individuals and families with early-onset osteoporosis or osteogenesis imperfecta (OI).<p class="abste...

ba0004oc9 | (1) | ICCBH2015

Skeletal manifestations in pediatric WNT1 osteoporosis

Makitie Riikka , Pekkinen Minna , Laine Christine , Makitie Outi

Objectives: We recently identified a heterozygous missense mutation c.652T→G (p. C218G) in WNT1 as the cause of severe primary osteoporosis (Laine et al. New Engl J Med 2013). The mutated WNT1 reduces activation of the canonical WNT1/β-catenin-signaling, resulting in decreased osteoblastic function. The mutation was originally identified in a large Finnish family presenting with dominantly inherited, early-onset osteoporosis, with affected...

ba0001oc2.1 | Bone quality and fracture repair - animal models | ECTS2013

Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of duchenne muscular dystrophy

Puolakkainen Tero , Ma Hongqiang , Pasternack Arja , Kainulainen Heikki , Ritvos Olli , Heikinheimo Kristiina , Hulmi Juha , Kiviranta Riku

Patients with Duchenne muscular dystrophy (DMD) carry a mutation in the dystrophin gene that leads to progressive muscle degeneration. In addition, DMD patients develop low bone mass especially in long bones and have high incidence of fractures. The underlying mechanisms for decreased bone mass remain unclear but muscle weakness and increased IL6 levels may play a role. Inhibition of activin/myostatin pathway has emerged as a novel approach to increase muscle mass and strength...

ba0001pp113 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

Lower bone turnover in obesity: is there a link to energy metabolism?

Viljakainen Heli , Ivaska Kaisa K , Lipsanen-Nyman Marita , Saukkonen Tero , Andersson Sture , Laitinen Kalevi , Makitie Outi

Background: Observations in rodents suggest that osteocalcin (OC) participates in glucose metabolism. Data from human studies are inconclusive and it remains unclear whether OC is simply a marker of bone turnover (BTM) or if it also mediates interactions between the skeleton and glucose homeostasis. This study determined the responses of BTMs, including OC, to oral glucose tolerance test (OGTT) in obese and normal-weight subjects.Materials and methods: P...

ba0005p315 | Osteoporosis: evaluation and imaging | ECTS2016

MRI analysis of the spine in 17 adults with WNT1 osteoporosis

Makitie Riikka , Niinimaki Tuukka , Nieminen Miika , Niinimaki Jaakko , Makitie Outi

Objectives: A heterozygous missense mutation p. C218G in WNT1 was recently identified as the cause of severe primary osteoporosis (Laine et al., New engl J Med 2013). The mutation has thus far been identified in two large Finnish families presenting with dominantly inherited, early-onset osteoporosis, with affected adult patients showing reduced bone mineral density (BMD), vertebral compression fractures, kyphosis and height loss. This study examined characte...